Impact of Depth Filtration on Disulfide Bond Reduction during Downstream Processing of Monoclonal Antibodies from CHO Cell Cultures
08th October 2018 | 9am PDT | Brian O' Mara, Senior Research Scientist I at Bristol-Myers Squibb and Alexei Voloshin, Global Application Strategy Specialist at 3M Separation and Purification Sciences Division |WATCH FOR FREE
• Understand disposable depth filtration technology used in the recovery of antibodies from CHO cell cultures as a unit operation leading to cellular lysis under particular operational conditions
• Study how cellular lysis occurring during depth filtration releases endogenous REDOX regulating enzymes and co-factors into the clarified harvest, resulting in the reduction of antibody interchain disulfide bonds
• Classify critical process parameters and quality attributes of the clarified harvest to be monitored during filtration development
• Discuss risk mitigation strategies to control antibody reduction when using single-use disposable technologies in the recovery of antibodies from CHO cells.
Presented by Brian O’ Mara, Senior Research Scientist I at Bristol-Myers Squibb
Brian is a Senior Scientist II in the Downstream Bioprocess Development group at Bristol-Myers Squibb in Seattle, WA. He has been working in the biotech industry since 2000 with previous experience including Wyeth (Pfizer), University of Rochester, and Genencor International (DuPont). He has worked on the development of a variety proteins for both clinical and commercial development including monoclonal antibodies, vaccines, enzymes, protein conjugates and radiolabeled diagnostics from both microbial and mammalian expression systems. Brian received his BS in Biology from Binghamton University and MS in Chemistry from Lehigh University
Sponsored by 3M
Presented by Alexei Voloshin, Global Application Strategy Specialist at 3M Separation and Purification Sciences Division
Alexei Voloshin is the Global Application Strategy Specialist at 3M Separation and Purification Sciences Division. He is responsible for product application strategy and manages technology projects, collaborations, and alliances around the globe. Alexei brings more than 15 years of experience in bio-process development, as well as technical, operational, and business knowledge in the biotechnology space. Before joining 3M, Alexei led molecular diagnostics program at Theranos Inc. He is also a founding member of TheraOne Inc., a start-up company focused on front line cancer immunotherapy. Before TheraOne, Alexei was an early member of Sutro Biopharma Inc., a company focused on development of novel biologics and bio-processes. There he was responsible for technology strategy and process development. He has authored a number of publications and presentations dealing with novel bio-processes and their applications to making advanced bio-therapeutics. Alexei got his Ph.D. in Chemical Engineering from Stanford University and Bachelor of Chemical Engineering and B.S. in Computer Science from University of Minnesota Twin Cities.